Adalimumab (Humira)

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Also Known As:

Networked: 5382 relevant articles (988 outcomes, 1123 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kupper, Hartmut: 46 articles (10/2020 - 11/2002)
2.	Sandborn, William J: 42 articles (11/2022 - 02/2003)
3.	Peyrin-Biroulet, Laurent: 35 articles (01/2022 - 04/2007)
4.	Danese, Silvio: 32 articles (11/2022 - 06/2009)
5.	Tanaka, Yoshiya: 31 articles (02/2022 - 06/2012)
6.	van der Heijde, Désirée: 30 articles (01/2021 - 07/2006)
7.	Panaccione, Remo: 28 articles (11/2022 - 02/2006)
8.	Fleischmann, Roy: 27 articles (04/2022 - 01/2007)
9.	Robinson, Anne M: 27 articles (01/2022 - 09/2009)
10.	Smolen, Josef S: 27 articles (01/2021 - 04/2003)

Related Diseases

1.	Crohn Disease (Crohn's Disease) 02/01/2017 - "Although adalimumab is effective in Crohn's disease, most patients experience a loss of response over time. " 10/01/2015 - "Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis." 08/01/2023 - "Metastatic Crohn's Disease in External Genitalia With Good Outcome on Adalimumab: A Rare Case of a Saudi Female and a Short Review." 10/06/2021 - "In individuals with Crohn's disease, higher adalimumab drug levels at week 4 (>13.9 μg/mL) were significantly associated with biological remission at week 24." 10/06/2021 - "Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease."
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 12/01/2014 - "Our data suggests that treatment with Adalimumab may promise best results in psoriasis-patients with (A) low baseline anti-dsDNA concentrations, and (B) no previous TNF-α antagonist treatment. " 11/01/2008 - "Adalimumab proved highly effective in psoriasis patients and in PsA patients previously unresponsive to nonsteroidal anti-inflammatory drugs. " 01/01/2009 - "The marked improvement of our two cases indicates that adalimumab may also help ameliorate nail psoriasis and warrants further controlled studies to establish the effectiveness and therapeutic regimes." 03/01/2020 - "Adalimumab is proven to be safe and effective in treating plaque psoriasis. " 12/09/2016 - "Adalimumab has proven effective in psoriasis; however, secondary failure may result from the drug's immunogenicity. "
3.	Rheumatoid Arthritis 07/01/2010 - "A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment." 01/01/2004 - "Moreover, the safety and tolerability of adalimumab in large clinical studies of rheumatoid arthritis have shown good results. " 11/01/2016 - "Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability." 11/01/2006 - "PDS detected a rapid and significant reduction in synovial perfusion at the wrist joints of patients with rheumatoid arthritis receiving adalimumab. " 01/01/2020 - "To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained remission. "
4.	Ulcerative Colitis 12/01/2022 - "A high adalimumab induction dosing regimen achieves clinical and endoscopic remission in super-refractory ulcerative colitis." 01/01/2022 - "SERENE UC (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Ulcerative Colitis) evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis. " 01/01/2013 - "Adalimumab treatment was associated with a positive benefit/risk balance in the overall population of patients with moderately-to-severely active ulcerative colitis in ULTRA 2; early response was predictive of a positive outcome at 1 year (NCT00408629)." 12/01/2011 - "More recently, data has been published demonstrating the efficacy of adalimumab in patients with ulcerative colitis." 12/01/2017 - "Adalimumab was effective in the treatment of moderate-to-severe ulcerative colitis. "
5.	Uveitis 07/07/2020 - "In uveitis, adalimumab was found to be the most efficacious agent for maintaining disease remission in adults and children with chronic non-infectious uveitis. " 08/01/2022 - "UWFA scores significantly improved in Behcet's uveitis patients treated with adalimumab, and further improvement of UWFA scores was found in patients with a clinically quiescent inflammatory state." 01/01/2022 - "Adalimumab, which was commenced in five patients with uveitis, resulted in significant improvement in four patients. " 01/01/2013 - "Even if limited to a relatively small group, our study suggests a better efficacy of Adalimumab when used as first anti-TNFα treatment in childhood chronic uveitis." 10/01/2013 - "The progressive course of the condition mandated considering other therapeutic measures; Adalimumab was chosen based on its purported efficacy for treatment of childhood uveitis and a favorable safety profile. "

Related Drugs and Biologics

1.	Infliximab (Remicade)
2.	Etanercept (Enbrel)
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Methotrexate (Mexate)
5.	Monoclonal Antibodies
6.	Ustekinumab (CNTO 1275)
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	golimumab
9.	Steroids
10.	Certolizumab Pegol

Related Therapies and Procedures

1.	Therapeutics
2.	Biological Therapy
3.	Drug Tapering
4.	Injections
5.	Activities of Daily Living (ADL)